Pomalidomide Capsule
Product Images NDC 0480-4035

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Pomalidomide (NDC 0480-4035). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Teva Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Str (Images 1)

FDA Label Image

Figure 1 (Images 2)

FDA Label Image

Figure 2 (Images 3)

This text provides statistical information comparing POMALID-DEX versus HD-DEX, including logrank p-value, hazard ratio (HR), median survival times, and event occurrence. The data presents overall survival in months for the subjects at risk in each group, along with the data cut-off date of March 1, 2013.*

FDA Label Image

1mg21s (Images 4)

This text provides information about Pomalidomide capsules with NDC 0480-4018-21, containing 1 mg of pomalidomide per capsule. It includes guidance for pharmacists to dispense medication with an accompanying Medication Guide, store the capsules at 20° to 25°C (68°F to 77°F), and information on dosage from prescribing information. The product is manufactured by Teva Pharmaceuticals in Parsippany, NJ.*

FDA Label Image

2mg21s (Images 5)

This text provides information about Pomalidomide capsules with a warning regarding the potential for human birth defects. It includes details on dispensing the medication guide to each patient, dosage, storage instructions, and manufacturer information (Teva Pharmaceuticals). The capsules contain 2 mg of pomalidomide, and prescribing information should be consulted for dosing and administration guidelines.*

FDA Label Image

3mg21s (Images 6)

This text contains information about Pomalidomide capsules with the NDC 0480-2601-21. It warns about the potential for human birth defects, advises pharmacists to dispense a medication guide to each patient, and provides details regarding dosage, storage, and manufacturing information. It also includes a reference to Teva Pharmaceuticals as the manufacturer.*

FDA Label Image

4mg21s (Images 7)

This is information for Pomalidomide capsules with NDC 0480-4035-21, containing 4 mg of pomalidomide per capsule. The warning advises on the potential for human birth defects. Pharmacists are directed to provide the accompanying Medication Guide to each patient. The usual dosage can be found in the prescribing information. These capsules are to be stored at 20° to 25°C and protected from excursions of 15° to 30°C. They should be dispensed in a tight, light-resistant container as per USP standards. The medication is manufactured by Teva Pharmaceuticals in Parsippany, NJ.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.